Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00931242 · ClinicalTrials.gov registry record · Phase 2
Study of Apremilast in Atopic or Contact Dermatitis
A Phase 2 study of Atopic Dermatitis and Allergic Contact Dermatitis, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00931242: Completed Phase 2 study of Atopic Dermatitis and Allergic Contact Dermatitis, sponsored by Tufts Medical Center.
NCT00931242 is a Phase 2 study of Atopic Dermatitis and Allergic Contact Dermatitis that has completed, run by Tufts Medical Center. The registered enrollment target is 10 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00931242, a Phase 2 study of Atopic Dermatitis and Allergic Contact Dermatitis, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the efficacy of apremilast in patients with recalcitrant atopic or contact dermatitis.
Primary Outcome
Improvement in IGA (Investigator Global Assessment) by two or more points on a five point scale, with 0 being no disease activity and 5 being maximum disease activity, at week 12
Conditions Studied
Interventions
- DRUG Apremilast
Study Locations (1)
Massachusetts
- Tufts Medical Center, Department of Dermatology - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00931242 record still lists
NCT00931242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Apremilast is the first listed.
NCT00931242 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00931242 about?
NCT00931242 is a clinical study titled "Study of Apremilast in Atopic or Contact Dermatitis". The objective of this study is to evaluate the efficacy of apremilast in patients with recalcitrant atopic or contact dermatitis.
What is the current status of trial NCT00931242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2009-06. Estimated completion is 2010-03.
What conditions does trial NCT00931242 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Allergic Contact Dermatitis.
What interventions are being tested in trial NCT00931242?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT00931242?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00931242 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00931242's enrollment target sits among peer trials
10 147th of 150 higher than 4 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia